VC
NBRV

Vivo Capital’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Vivo Capital’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,817
Closed -$980K – 62
2020
Q1 		$980K Buy
+6,817
New +$2.09M 0.09% 52
2019
Q3 		– Sell
-16,157
Closed -$9.81M – 45
2019
Q2 		$9.81M Sell
16,157
-1,458
-8% -$894K 0.92% 28
2019
Q1 		$10.7M Sell
17,615
-8,862
-33% -$4.83M 1.07% 24
2018
Q4 		$9.66M Hold
26,477
– – 1.23% 23
2018
Q3 		$17.9M Buy
26,477
+10,180
+62% +$7.22M 1.8% 19
2018
Q2 		$14.2M Hold
16,297
– – 1.83% 16
2018
Q1 		$20.5M Hold
16,297
– – 2.9% 9
2017
Q4 		$24.4M Hold
16,297
– – 5.22% 7
2017
Q3 		$33.4M Buy
16,297
+211
+1% +$495K 6.74% 4
2017
Q2 		$42.1M Hold
16,086
– – 10.61% 4
2017
Q1 		$48.3M Hold
16,086
– – 14.2% 3
2016
Q4 		$24M Buy
16,086
+3,479
+28% +$4.62M 7.9% 4
2016
Q3 		$22.2M Hold
12,607
– – 6.92% 5
2016
Q2 		$23.6M Hold
12,607
– – 6.46% 4
2016
Q1 		$28.2M Buy
+12,607
New +$27.1M 7.08% 4

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Vivo Capital's NBRV Position: Q2 2020 in Review

Vivo Capital sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2020, closing a stake of 6,817 shares — an estimated $980K sold.

Vivo Capital first reported a position in NBRV in Q1 2016 and held it in 15 quarters. The position peaked at $48.3M in Q1 2017. 53 funds tracked by Wall St. Rank hold NBRV as of Q2 2020.

  • Vivo Capital reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2020 after selling out during the quarter.
  • Vivo Capital sold 6,817 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2020, an estimated $980K.
  • Vivo Capital first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2016 and held it in 15 quarters.
  • Vivo Capital's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $48.3M in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2020.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.